| Literature DB >> 26797241 |
Sheetal M Kircher1, Caitlin R Meeker2, Halla Nimeiri3, Daniel M Geynisman2, S Yousuf Zafar4, Veena Shankaran5, Jonas de Souza6, Yu-Ning Wong2.
Abstract
Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.Entities:
Keywords: drug costs; neoplasms
Mesh:
Substances:
Year: 2015 PMID: 26797241 DOI: 10.1016/j.jval.2015.10.005
Source DB: PubMed Journal: Value Health ISSN: 1098-3015 Impact factor: 5.725